抗VEGF治疗应答异质性在糖尿病性黄斑水肿中的研究进展

doi:10.11958/20253432

天津医药 ›› 2026, Vol. 54 ›› Issue (7): 779-784.doi: 10.11958/20253432

• 综述 • 上一篇

抗VEGF治疗应答异质性在糖尿病性黄斑水肿中的研究进展

何紫叶¹^,²(), 祖洁², 郝倩¹, 贾志旸²^,^△()

¹ 华北理工大学临床医学院（邮编063210）
² 河北省人民医院眼科

收稿日期:2025-11-28 修回日期:2025-12-25 出版日期:2026-07-15 发布日期:2026-07-13
通讯作者: ^△E-mail：jiazhiyang20759@sina.com
作者简介:何紫叶（1998），女，硕士在读，主要从事玻璃体视网膜疾病方面研究。E-mail：m15132256951@163.com
基金资助:
河北省医学科学研究课题计划基金资助项目(20260049)

Research progress on the heterogeneity of anti-vascular endothelial growth factor therapy response in diabetic macular edema

HE Ziye¹^,²(), ZU Jie², HAO Qian¹, JIA Zhiyang²^,^△()

¹ College of Clinical Medicine, North China University of Science and Technology, Tangshan 063210, China
² Department of Ophthalmology, Hebei General Hospital

Received:2025-11-28 Revised:2025-12-25 Published:2026-07-15 Online:2026-07-13
Contact: ^△E-mail：jiazhiyang20759@sina.com

何紫叶, 祖洁, 郝倩, 贾志旸. 抗VEGF治疗应答异质性在糖尿病性黄斑水肿中的研究进展[J]. 天津医药, 2026, 54(7): 779-784.

HE Ziye, ZU Jie, HAO Qian, JIA Zhiyang. Research progress on the heterogeneity of anti-vascular endothelial growth factor therapy response in diabetic macular edema[J]. Tianjin Medical Journal, 2026, 54(7): 779-784.

摘要/Abstract

摘要：

糖尿病性视网膜病变（DR）是糖尿病患者常见的眼部并发症之一，可引起视功能的严重受损。在DR患者中，糖尿病性黄斑水肿（DME）是导致中心视力损害最常见的原因，抗血管内皮生长因子（VEGF）治疗为当前DME的一线治疗方法。抗VEGF药物治疗存在显著的应答异质性，提示眼部或全身因素可能影响患者的治疗反应。目前，针对相关影响因素的分析尚未充分阐明，该文就导致DME患者抗VEGF治疗应答异质性的全身及眼部影响因素进行综述。

关键词: 糖尿病视网膜病变, 黄斑水肿, 体层摄影术, 光学相干, 血管内皮生长因子类, 治疗反应

Abstract:

Diabetic retinopathy (DR) is one of the common ocular complications in diabetic patients, which can cause severe impairment of visual function. Among DR patients, diabetic macular edema (DME) is the most common cause of central vision impairment. Anti-vascular endothelial growth factor (VEGF) therapy is currently the first-line treatment for DME. However, anti-VEGF therapy shows significant heterogenelty in treatment response, suggesting that ocular or systemic factors may be involved. At present, the analysis of relevant influencing factors has not been fully elucidated. This article reviews the ocular and systemic factors that contribute to the heterogeneous response to anti-VEGF treatment in DME patients.

Key words: diabetic retinopathy, macular edema, tomography, optical coherence, vascular endothelial growth factors, treatment response

中图分类号:

R774.5，R587.2

参考文献 46

[1]	Dervis N, Jurja S, Chisnoiu T, et al. Serum vitamin D levels as predictors of response to intravitreal anti-VEGF therapy in diabetic macular edema:A clinical correlation study[J]. Int J Mol Sci, 2025, 26(17):8481. doi:10.3390/ijms26178481.
[2]	Yan A, Jones C, Demirel S, et al. Diabetic macular edema:Upcoming therapies[J]. Graefes Arch Clin Exp Ophthalmol, 2025, 263(2):249-258. doi:10.1007/s00417-024-06595-7.
[3]	Chen K Y, Chan H C, Chan C M. Which treatment modality offers the best outcomes for diabetic retinopathy? A systematic review and network meta-analysis[J]. Diabetes Res Clin Pract, 2025, 227:112379. doi:10.1016/j.diabres.2025.112379.
[4]	Cheema A A, Cheema H R. Diabetic macular edema management:A review of anti-vascular endothelial growth factor(VEGF)therapies[J]. Cureus, 2024, 16(1):e52676. doi:10.7759/cureus.52676.
[5]	Chen Y P, Wu A L, Chuang C C, et al. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab:comparison between responder and non-responder cases[J]. Sci Rep, 2019, 9(1):10952. doi:10.1038/s41598-019-47241-1.
[6]	Liu D, Maguire M G, Jonna G, et al. Association of patient age with response to anti-vascular endothelial growth factor agents for treatment of diabetic macular edema[J]. Retina, 2025. doi:10.1097/IAE.0000000000004707.[Online ahead of print].
[7]	Sophie R, Lu N, Campochiaro P A. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab[J]. Ophthalmology, 2015, 122(7):1395-1401. doi:10.1016/j.ophtha.2015.02.036.
[8]	Gurung R L, Fitzgerald L M, Liu E, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice[J]. Int J Retina Vitreous, 2023, 9(1):23. doi:10.1186/s40942-023-00453-0.
[9]	Cunha-Vaz J, Ashton P, Iezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants:long-term benefit in patients with chronic diabetic macular edema[J]. Ophthalmology, 2014, 121(10):1892-1903. doi:10.1016/j.ophtha.2014.04.019.
[10]	黄玥, 沈碧波, 赵东升. 糖尿病黄斑水肿对抗VEGF药物治疗的不同反应与糖尿病视网膜病变程度的相关性[J]. 国际眼科杂志, 2017, 17(2):348-350.
	Huang Y, Shen B B, Zhao D S. Correlation between responses to intravitreal injection of anti-VEGF and diabetic retinopathy extent in diabetic macular edema patients[J]. Int Eye Sci, 2017, 17(2):348-350.
[11]	Jakobsen T S, Adsersen R L, Askou A L, et al. Functional roles of pigment epithelium-derived factor in retinal degenerative and vascular disorders:A scoping review[J]. Invest Ophthalmol Vis Sci, 2024, 65(14):41. doi:10.1167/iovs.65.14.41.
[12]	Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology:vasogenic versus inflammatory[J]. J Diabetes Res, 2016, 2016:2156273. doi:10.1155/2016/2156273.
[13]	Liu X, Chen H H, Zhang L W. Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy[J]. Int J Ophthalmol, 2013, 6(2):221-227. doi:10.3980/J.ISSN.2222-3959.2013.02.22.
[14]	Gu W, Wang M, Li Z, et al. The association between peripheral blood inflammatory markers and anti-VEGF treatment response in patients with type 2 diabetic macular edema[J]. Front Med(Lausanne), 2025, 12:1653753. doi:10.3389/fmed.2025.1653753.
[15]	Katić K, Katić J, Kumrić M, et al. The predictors of early treatment effectiveness of intravitreal bevacizumab application in patients with diabetic macular edema[J]. Diagnostics(Basel), 2024, 14(10):992. doi:10.3390/diagnostics14100992.
[16]	Ergin E, Dascalu A M, Stana D, et al. Predictive role of complete blood count-derived inflammation indices and optical coherence tomography biomarkers for early response to intravitreal anti-VEGF in diabetic macular edema[J]. Biomedicines, 2025, 13(6):1308. doi:10.3390/biomedicines13061308.
[17]	González P, Lozano P, Ros G, et al. Hyperglycemia and oxidative stress:An integral,updated and critical overview of their metabolic interconnections[J]. Int J Mol Sci, 2023, 24(11):9352. doi:10.3390/ijms24119352.
[18]	Dagher C, Akiki M, Saliby R, et al. The impact of glycemic control on ranibizumab efficacy in diabetic retinopathy:A retrospective analysis[J]. Cureus, 2025, 17(1):e77124. doi:10.7759/cureus.77124.
[19]	Debourdeau E, Medard R, Chamard C, et al. Does HbA1c level or glomerular filtration rate affect the clinical response to endothelial growth factor therapy(Ranibizumab or Aflibercept)in diabetic macular edema? A real-life experience[J]. Ophthalmol Ther, 2023, 12(5):2657-2670. doi:10.1007/s40123-023-00758-1.
[20]	Gomez-Peralta F, Choudhary P, Cosson E, et al. Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin[J]. Diabetes Obes Metab, 2022, 24(4):599-608. doi:10.1111/dom.14638.
[21]	Giacco F, Brownlee M. Oxidative stress and diabetic complications[J]. Circ Res, 2010, 107(9):1058-1070. doi:10.1161/CIRCRESAHA.110.223545.
[22]	Bressler S B, Qin H, Beck R W, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab[J]. Arch Ophthalmol, 2012, 130(9):1153-1161. doi:10.1001/archophthalmol.2012.1107.
[23]	Wang X N, Cai X, He S, et al. Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation[J]. Int Ophthalmol, 2023, 43(12):4399-4407. doi:10.1007/s10792-021-01806-0.
[24]	张怡, 姚静, 权彦龙, 等. 基于光学相干断层扫描的不同类型糖尿病性黄斑水肿对康柏西普的治疗反应[J]. 南方医科大学学报, 2021, 41(10):1501-1508.
	Zhang Y, Yao J, Quan Y L, et al. Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography[J]. J South Med Univ, 2021, 41(10):1501-1508. doi:10.12122/j.issn.1673-4254.2021.10.08.
[25]	Zhou Z H, Zhao L, Wang Y L, et al. Predictive impact of serous retinal detachment in refractory diabetic macular edema[J]. BMC Ophthalmol, 2025, 25(1):177. doi:10.1186/s12886-025-03993-1.
[26]	Sharma S, Karki P, Joshi S N, et al. Optical coherence tomography patterns of diabetic macular edema and treatment response to bevacizumab:a short-term study[J]. Ther Adv Ophthalmol, 2022, 14:25158414221074519. doi:10.1177/25158414221074519.
[27]	Wang Y, Li F, Hao M, et al. Predictive value of hyperreflective foci for anti-VEGF therapeutic outcomes in different subtypes of diabetic macular edema: a retrospective analysis[J]. Front Endocrinol(Lausanne), 2025, 16:1648828. doi:10.3389/fendo.2025.1648828.
[28]	Sonoda S, Sakamoto T, Yamashita T, et al. Retinal morphologic changes and concentrations of cytokines in eyes with diabetic macular edema[J]. Retina, 2014, 34(4):741-748. doi:10.1097/IAE.0b013e3182a48917.
[29]	Sepah Y J, Do D V, Mesquida M, et al. Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy[J]. Eye(Lond), 2024, 38(9):1755-1761. doi:10.1038/s41433-024-03015-2.
[30]	Yao J, Huang W, Gao L, et al. Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography:A network meta-analysis[J]. PLoS One, 2024, 19(6):e0304283. doi:10.1371/journal.pone.0304283.
[31]	Chou J F, Wu J S, Chen Y L, et al. Modified early intensive and treat-and-extend regimen of anti-vascular endothelial growth factor for diabetic macular edema in Taiwan[J]. Sci Rep, 2023, 13(1):19349. doi:10.1038/s41598-023-43931-z.
[32]	Midena E, Torresin T, Schiavon S, et al. The disorganization of retinal inner layers is correlated to müller cells impairment in diabetic macular edema:An imaging and omics study[J]. Int J Mol Sci, 2023, 24(11):9607. doi:10.3390/ijms24119607.
[33]	Lu W, Xiao K, Zhang X, et al. A machine learning model for predicting anatomical response to anti-VEGF therapy in diabetic macular edema[J]. Front Cell Dev Biol, 2025, 13:1603958. doi:10.3389/fcell.2025.1603958.
[34]	Wall K, Arend L P, Von Der Emde L, et al. Characterization of the disorganization of the inner retinal layers in diabetics using increased axial resolution optical coherence tomography[J]. Transl Vis Sci Technol, 2025, 14(1):12. doi:10.1167/tvst.14.1.12.
[35]	Nicholson L, Ramu J, Triantafyllopoulou I, et al. Diagnostic accuracy of disorganization of the retinal inner layers in detecting macular capillary non-perfusion in diabetic retinopathy[J]. Clin Exp Ophthalmol, 2015, 43(8):735-741. doi:10.1111/ceo.12557.
[36]	Jatoi A. Association between integrity of foveal photoreceptors and ultimate visual outcome in neovascular age-related macular degeneration[J]. Vestn Oftalmol, 2025, 141(1):32-36. doi:10.17116/oftalma202514101132.
[37]	Hsieh T C, Deng G H, Chang Y C, et al. A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-VEGF treatment[J]. Front Endocrinol(Lausanne), 2023, 14:1108097. doi:10.3389/fendo.2023.1108097.
[38]	Maheshwary A S, Oster S F, Yuson R M, et al. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema[J]. Am J Ophthalmol, 2010, 150(1):63-67.e1. doi:10.1016/j.ajo.2010.01.039.
[39]	Mat Nor M N, Guo C X, Green C R, et al. Hyper-reflective dots in optical coherence tomography imaging and inflammation markers in diabetic retinopathy[J]. J Anat, 2023, 243(4):697-705. doi:10.1111/joa.13889.
[40]	Maguire M, Laidlaw D, Davies N, et al. The impact of vitreo-macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema[J]. Graefes Arch Clin Exp Ophthalmol, 2024, 262(11):3501-3508. doi:10.1007/s00417-024-06518-6.
[41]	Wang Q, Wang C, Su Y, et al. Topographic correlation of microperimetry with foveal microstructure characteristics in idiopathic epiretinal membrane patients with an ectopic inner foveal layer[J]. Eye Vis(Lond), 2025, 12(1):4. doi:10.1186/s40662-024-00419-9.
[42]	Liu D, Chen X, Cai S. Inhibition of retinal neovascularization by Dendrobium polysaccharides:a review[J]. Front Pharmacol, 2025, 16:1584553. doi:10.3389/fphar.2025.1584553.
[43]	Watanabe A, Takashina H, Nakano T. Effect of microaneurysms on the anti-VEGF treatment for diabetic macular edema:A retrospective cross-sectional study[J]. Medicine(Baltimore), 2023, 102(44):e35888. doi:10.1097/MD.0000000000035888.
[44]	Allingham M J, Mukherjee D, Lally E B, et al. A quantitative approach to predict differential effects of anti-VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema:A pilot study[J]. Transl Vis Sci Technol, 2017, 6(2):7. doi:10.1167/tvst.6.2.7.
[45]	Rana V, Agarwal A, Arora A, et al. Predicting visual outcomes following anti-vascular endothelial growth factor treatment for diabetic macular edema[J]. Indian J Ophthalmol, 2024, 72(Suppl 1):S16-S21. doi:10.4103/IJO.IJO_893_23.
[46]	Takamura Y, Yamada Y, Inatani M. Role of microaneurysms in the pathogenesis and therapy of diabetic macular edema:A descriptive review[J]. Medicina(Kaunas), 2023, 59(3):435. doi:10.3390/medicina59030435.

抗VEGF治疗应答异质性在糖尿病性黄斑水肿中的研究进展

Research progress on the heterogeneity of anti-vascular endothelial growth factor therapy response in diabetic macular edema

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 46

相关文章 15

编辑推荐

Metrics

本文评价

[1]	胡金宝, 柳文武, 胡志超. 视网膜静脉阻塞患者血清微小RNA表达水平与黄斑水肿程度的相关性[J]. 天津医药, 2026, 54(7): 741-746.
[2]	孟斌, 刘昕, 郭寅, 吉昂. 纤维血管性视网膜色素上皮脱离患者抗VEGF治疗后色素上皮撕裂的特征因素分析[J]. 天津医药, 2026, 54(7): 747-750.
[3]	康晓娜, 刘亚萍, 冯云, 罗玉梅, 贾皑. 基于超声内镜与增强CT构建胃肠道间质瘤恶性潜能的术前评估模型[J]. 天津医药, 2026, 54(6): 637-642.
[4]	许正杰, 李田, 畅立斌. DEX-I联合雷珠单抗治疗视网膜血管性疾病继发黄斑水肿的疗效观察[J]. 天津医药, 2026, 54(6): 647-652.
[5]	张文延, 李祖贵, 贾永春, 江伟, 甄雨生, 许亮. 成人Still病活动度及复发风险与¹⁸F-FDG PET/CT代谢参数的相关性研究[J]. 天津医药, 2026, 54(3): 283-288.
[6]	马良, 胡立影, 石羽, 赵永安, 孙雅斯, 孙广东. 不同血压水平糖尿病肾病患者黄斑区视网膜厚度特征分析[J]. 天津医药, 2025, 53(9): 923-926.
[7]	解鹏亮, 郑陆芳, 李琰, 郑艳瑾, 白领娣, 赵霞, 路迎龙. 血管内皮生长因子与糖尿病黄斑囊样水肿严重程度的相关性[J]. 天津医药, 2025, 53(9): 927-931.
[8]	朱芳芳, 李世大, 陈秀英. 丹归祛瘀丸联合针刺治疗子宫腺肌病的疗效观察[J]. 天津医药, 2025, 53(7): 765-769.
[9]	王海诚, 赵一涵, 谢妹伊, 赵宇明. ¹⁸F-PSMA-1007 PET/CT的SUVmax和SUVmean参数对前列腺癌诊断及病情进展的预测价值[J]. 天津医药, 2025, 53(6): 614-618.
[10]	刘鑫, 马宇, 路凯, 张桂成, 吴悦, 胡方梅, 崔友祥, 孙云川. CTP、CTA联合血清NSE对脑卒中偏瘫患者侧支循环状态及预后的评估价值[J]. 天津医药, 2025, 53(6): 629-633.
[11]	杜凌云, 王耀武, 任楠. 肾透明细胞癌中PRMT2、TRAF2与转移相关基因表达对预后的评估价值[J]. 天津医药, 2025, 53(5): 492-497.
[12]	孙鲁生, 张丽芳, 高俊杰, 汤秀英. CT定量左心结构参数与肥厚型心肌病并心房颤动射频消融术后复发的关系[J]. 天津医药, 2025, 53(5): 533-536.
[13]	冯华, 王魁, 徐文俊, 李能, 张恒喜. 床旁超声造影联合气水交替注射法在重症鼻肠管留置患者中的应用效果[J]. 天津医药, 2025, 53(5): 542-546.
[14]	李小硕, 韩子旭, 李洋, 李梦宁. 椎体CT参数对TLIF术后早期融合器沉降的预测价值[J]. 天津医药, 2025, 53(3): 301-306.
[15]	王琳娜, 王迪, 董彦宏. 艾立布林联合NP方案治疗晚期乳腺癌患者的临床效果[J]. 天津医药, 2025, 53(3): 326-330.